Mirum Pharmaceuticals is executing strongly on the commercial front, with revenue accelerating 37.9% year-over-year to $176.2M in 2026Q2 and gross margins expanding to 82.8%, reflecting scale and favorable product mix. However, the company's aggressive investm...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 37.9% year-over-year in 2026Q2, reaching $176.2M, while gross margin expanded to 82.8% from 74.2% in 2024Q1, though operating margin remained deeply negative at -24.1% due to elevated R&D and SG&A spending.
Mirum Pharmaceuticals and Incyte announced pivotal late-breaking results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva, accepted for presentation at ENDO 2026.
MarketBeat provides the latest MIRM stock analysis, price targets, earnings estimates, and headlines, indicating ongoing investor interest and potential upside.
Mirum maintains active investor relations with accessible contacts and stock quote information, suggesting transparency and engagement with shareholders.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$1.06-42.8% vs -$0.74 | $176M+5.9% vs $166M |
Q2 2026 May 6, 2026 | -$13.43-3257.5% vs -$0.40 | $160M+7.9% vs $148M |
Q1 2026 Feb 25, 2026 | -$0.11-650.0% vs $0.02 | $149M+4.5% vs $143M |
Q4 2025 Nov 4, 2025 | $0.05+150.0% vs -$0.10 | $133M-5.6% vs $141M |
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Mirum Pharmaceuticals is approaching major catalysts, notably the FDA's PDUFA decision for zilurgisertib (Sept. 26) & pivotal Phase 3 data on its chronic hepatitis D drug, a potential blockbuster. MIRM's pipeline expansion and strategic acquisitions have delayed profitability to 2028, but management raised FY 2026 sales guidance to $680–$700 million. Strong commercial traction from LIVMARLI and bile acid products drove Q2 revenue above expectations, but operating losses widened due to R&D and integration costs.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Benchmark MIRM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mirum Pharmaceuticals, Inc. (MIRM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $89.32 | $5.45B | -190.04 | 54.74% | -4.48% | -8.65% | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — |
Mirum Pharmaceuticals, Inc. (MIRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mirum Pharmaceuticals, Inc. (MIRM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 18, 2026·SEC
May 18, 2026·SEC
Get notified when MIRM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mirum Pharmaceuticals, Inc. (MIRM) stock FAQ — growth, dividends, profitability & financials explained
Mirum Pharmaceuticals, Inc. (MIRM) reported $618.1M in revenue for fiscal year 2025.
Mirum Pharmaceuticals, Inc. (MIRM) grew revenue by 54.7% over the past year. This is strong growth.
Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $860.2M for fiscal year 2025.
Mirum Pharmaceuticals, Inc. (MIRM) has a return on equity (ROE) of -8.6%. Negative ROE indicates the company is unprofitable.
Mirum Pharmaceuticals, Inc. (MIRM) had negative free cash flow of $458.2M in fiscal year 2025, likely due to heavy capital investments.
